Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


It’s Official: FDA Approval Does Not Equal CMS Coverage

This article was originally published in RPM Report

Executive Summary

Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.

You may also be interested in...

Straight Talk About Cancer Drug Coverage

CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.

The Gene Therapy Wave Is Here

The long-talked about wave of gene therapy approvals is beginning to reveal itself.

Will The Excise Tax Torpedo The IRA Drug Price Negotiation Program?

A case involving a tax that was an “exceedingly heavy burden” and played into the Supreme Court’s original ruling on the ACA could reemerge once the IRA challenge reaches the high court.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts